GlassScriptPhysician profile
Jeffrey D Cizenski
NPI 1821437104
$1,030,844.48
in general payments reported to CMS, 2019-2025
39 companies · $277K in 2025
The $277K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $39K · 2021: $74K · 2022: $193K · 2023: $248K · 2024: $200K · 2025: $277K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $618K · Travel and Lodging: $48K · Consulting Fee: $27K · Food and Beverage: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $16K · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $617,788.50 |
| Travel and Lodging | $47,712.76 |
| Consulting Fee | $26,950.52 |
| Food and Beverage | $16,854.26 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,523.00 |
| Education | $107.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $220,633.85 | 2019-2025 | Otezla, Otezla |
| Abbvie INC. | $167,936.05 | 2019-2025 | Rinvoq, Skyrizi |
| Incyte Corporation | $124,029.09 | 2021-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $81,398.92 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $79,731.38 | 2020-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $65,696.03 | 2022-2024 | Vtama |
| Ucb, INC. | $59,483.52 | 2020-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $53,337.42 | 2020-2025 | Tremfya, Remicade, Stelara |
| Sun Pharmaceutical Industries INC. | $48,897.73 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Genzyme Corporation | $41,906.55 | 2019-2025 | |
| Galderma Laboratories, L.P. | $38,764.61 | 2019-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $36,100.17 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $4,436.34 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $3,570.53 | 2019-2025 | |
| Pfizer INC. | $3,386.75 | 2020-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $318.35 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Arcutis Biotherapeutics, INC. | $266.72 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $251.44 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.85 | 2022-2025 | Spevigo |
| Organon LLC | $75.12 | 2025 | Vtama |
| Misonix INC | $57.39 | 2021 | |
| Prugen, INC. Pharmaceuticals | $56.70 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $56.39 | 2021 | |
| Janssen Scientific Affairs, LLC | $54.83 | 2023-2024 | Tremfya |
| Blueprint Medicines Corporation | $41.40 | 2023-2024 | Ayvakit |
| Fresenius Kabi USA, LLC | $32.86 | 2023 | |
| Celgene Corporation | $23.97 | 2019 | |
| Dusa Pharmaceuticals, INC. | $21.96 | 2019 | |
| Organogenesis INC. | $19.54 | 2021 | |
| Nabriva Therapeutics, Plc | $17.95 | 2022 | |
| Dermira, INC. | $16.70 | 2020 | |
| Botanix Sb INC | $15.17 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $15.05 | 2022 | |
| Krystal Biotech INC | $14.34 | 2025 | Vyjuvek |
| Myriad Genetic Laboratories, INC. | $14.11 | 2021 | |
| Mimedx Group, INC. | $13.77 | 2025 | |
| Ascensia Diabetes Care US INC. | $13.51 | 2024 | |
| Almirall LLC | $13.42 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cizenski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.